Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Galm

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Onkologie|June 27, 2009
Cisplatin as single-agent chemotherapy in patients with liver dysfunction due to metastasesStefan Wilop, Reyad Dada, Oliver Galm, et al.
Acta Haematologica|November 6, 2009
Successful treatment of hepatic encephalopathy in a patient with acute lymphoblastic leukemiaReyad Dada, Stefan Wilop, Edgar Jost, et al.
Clinical Epigenetics|June 19, 2012
Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemiaChristoph Oing, Edgar Jost, Edgar Dahl, et al.
American Journal of Hematology|June 25, 2010
Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)Iris Middeldorf, Oliver Galm, Rainhardt Osieka, et al.
Blood|January 30, 2010
Friday leukemia: myth or reality?Stefan Wilop, Oliver Galm, Laura Thompson, et al.
Clinical Epigenetics|September 1, 2012
Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutationKarla Bennemann, Oliver Galm, Stefan Wilop, et al.
BMC Cancer|June 9, 2009
Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancerJason P W Carey, Ananthi J Asirvatham, Oliver Galm, et al.
Pain and Therapy|November 18, 2021
Comparative Benefit-Risk Assessment for Lidocaine 700 mg Medicated Plaster and Pregabalin in Peripheral Neuropathic Pain Following a Structured Framework ApproachIngo Sabatschus, Irmgard Bösl, Marlou Prevoo, et al.
Breast Cancer Research : BCR|June 17, 2009
Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancerFrank Wiesmann, Jürgen Veeck, Oliver Galm, et al.
Leukemia Research|September 2, 2008
Aberrant DNA methylation of the transcription factor C/EBPalpha in acute myelogenous leukemiaEdgar Jost, Nicole do O, Stefan Wilop, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Onkologie|June 27, 2009
Cisplatin as single-agent chemotherapy in patients with liver dysfunction due to metastasesStefan Wilop, Reyad Dada, Oliver Galm, et al.
Acta Haematologica|November 6, 2009
Successful treatment of hepatic encephalopathy in a patient with acute lymphoblastic leukemiaReyad Dada, Stefan Wilop, Edgar Jost, et al.
Clinical Epigenetics|June 19, 2012
Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemiaChristoph Oing, Edgar Jost, Edgar Dahl, et al.
American Journal of Hematology|June 25, 2010
Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)Iris Middeldorf, Oliver Galm, Rainhardt Osieka, et al.
Blood|January 30, 2010
Friday leukemia: myth or reality?Stefan Wilop, Oliver Galm, Laura Thompson, et al.
Clinical Epigenetics|September 1, 2012
Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutationKarla Bennemann, Oliver Galm, Stefan Wilop, et al.
BMC Cancer|June 9, 2009
Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancerJason P W Carey, Ananthi J Asirvatham, Oliver Galm, et al.
Pain and Therapy|November 18, 2021
Comparative Benefit-Risk Assessment for Lidocaine 700 mg Medicated Plaster and Pregabalin in Peripheral Neuropathic Pain Following a Structured Framework ApproachIngo Sabatschus, Irmgard Bösl, Marlou Prevoo, et al.
Breast Cancer Research : BCR|June 17, 2009
Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancerFrank Wiesmann, Jürgen Veeck, Oliver Galm, et al.
Leukemia Research|September 2, 2008
Aberrant DNA methylation of the transcription factor C/EBPalpha in acute myelogenous leukemiaEdgar Jost, Nicole do O, Stefan Wilop, et al.
Pageof 4